TCG Lifesciences Private Limited (formerly “Chembiotek Research International”) is a leading Contract Research and Manufacturing Services (“CRAMS”) company in the area of early drug discovery and development. We started our operations in the year 2001 in India; currently we have our presence in United States, Europe, Japan and Australia.
We have a strong talent pool of 800 + qualified and trained scientists (including 150 + PhDs) , drawn from the best national and international institutes and industry.
Spread over 250,000 sq. ft. of space our services span from specific solutions to integrated discovery projects across multiple therapeutic areas with focus on Inflammation & Pain, Infectious Diseases and Central Nervous System (CNS) and we are presently initiating the setting up of the oncology platform. Our research infrastructure includes world class chemistry and biology laboratories, animal facility, electrophysiology laboratory, BSL 2 laboratory, and cGMP facilities at our R&D centers in Kolkata. Our API manufacturing subsidiary ‘Clininvent’ is located in Hyderabad, India.
Partner with global pharma and biotechnology companies and collaboratively discover new molecules to address the unmet medical needs. Collaborate with bio-medical researchers, research institutions and academia to accelerate generation of knowledge and leverage innovation and technology platforms.
We are a part of ‘The Chatterjee Group’ (TCG), a global investment conglomerate headquartered in New York with strategic investments of over USD 1 Billion. The group is established by Dr. Purnendu Chatterjee. TCG is internationally known for generating significant capital appreciation through long term strategic investments, both in the private and public sectors. Dr. Chattejee has made several strategic investments in India, particularly in knowledge intensive industries, such as Information Technology, IT enabled services, Life Sciences, Real Estate and Petrochemicals amongst others.